{"prompt": "['LIST OF TABLES AND FIGURES', 'Table 4-A: Treatment Administration', '17', 'Table 5-A: Dose Modifications for BV - Nausea', '21', 'Table 5-B: Dose Modifications for BV - Vomiting', '21', 'Table 5-C: Dose Modifications for BV - Anemia', '22', 'Table 5-D: Dose Modifications for BV - Neutropenia', '22', 'Table 5-E: Dose Modifications for BV - Thrombocytopenia', '23', 'Table 5-F: Dose Modifications for Vincristine - Peripheral Neuropathy', '23', 'Table 5-G: Dose Modifications for Vincristine - Constipation or Ileus', '24', 'Table 5-H: Elevated Total Bilirubin', '24', 'Table 5-I: Dose Modifications for Bleomycin - Pulmonary Toxicity', '25', 'Table 5-J: Dose Modifications for Bleomycin - Renal Insufficiency', '25', 'Table 6-A: Adverse Event List for Vincristine', '26', 'Table 6-B: Adverse Event List for Bleomycin', '26', 'Table 6-C: Attribution', '28', 'Table 12-A: Accrual Targets', '42', 'AMC-S007 (Version 2.0) 20MAR2018', '5', 'NCI Version Date 20MAR2018']['PROTOCOL ROSTER', 'AMC Protocol #S007', 'Longitudinal Quality of Life Study Among Participants with AIDS-Associated Kaposi', 'Sarcoma at Bugando Medical Centre, in Mwanza, Tanzania', 'Protocol Chair:', 'Protocol Statistician:', 'Kristin Schroeder MD, MPH', 'Jeannette Y. Lee, PhD', 'AIDS Malignancy Consortium', 'AMC Statistical Center', 'P.O. Box 1370', 'University of Arkansas for Medical Sciences', 'Mwanza, Tanzania', '4301 W. Markham, #781', 'Tel: 255-686-3-86349', 'Little Rock, Arkansas 72205-7199', 'Email: kristin.schroeder@dm.duke.edu', 'Tel: (501)526-6712', 'Fax: (501) 526-6729', 'Email: JYLee@uams.edu', 'Protocol Co-Chair:', 'Data Management/Operations:', 'Nestory Masalu MD, MMed', 'AMC Operations and Data Management', 'Bugando Medical Centre', 'Center', 'P.O. Box 1370', 'The Emmes Corporation', 'Mwanza, Tanzania', '401 N. Washington Street, Suite 700', 'Tel: 255-783-0-00004', 'Rockville, MD 20850', 'Email: nmasaslu4@gmail.com', 'Tel: (301)251-1161', 'Fax: (240) 238-2842', 'Email: amipm@emmes.com', 'AMC Kaposi Sarcoma Working Group', 'Chair:', 'Lee Ratner, MD, PhD', 'Washington University School of Medicine', 'Division of Oncology', '660 S. Euclid Avenue', 'Campus Box 8069', 'St. Louis, MO 63110', 'Tel: 314-362-8836', 'Fax: 314-747-2120', 'Email: lratner@dom.wustl.edu', 'AMC-S007 (Version 2.0) 20MAR2018', '6', 'NCI Version Date 20MAR2018']['PROTOCOL SYNOPSIS', 'TITLE:', 'Longitudinal Quality of Life Study Among Participants with', 'AIDS-Associated Kaposi Sarcoma at Bugando Medical Centre,', 'in Mwanza, Tanzania', 'PHASE OF STUDY:', 'Pilot', 'PARTICIPATING', 'This protocol will be open at the Bugando Medical Centre in', 'INSTITUTIONS:', 'Mwanza, Tanzania', 'ACCRUAL TARGET:', 'Minimum: 12, Maximum: 20', 'POPULATION:', 'Participants with KS who are HIV-positive initiating', 'chemotherapy with bleomycin and vincristine sulfate (BV). See', 'Section 3.0 for eligibility criteria.', 'REGIMEN:', 'Participants will receive standard therapy for KS: bleomycin (15', 'units/m\u00b2) and vincristine (2mg fixed dose) infused intravenously', 'every 21 days for a maximum of six cycles. A Quality of Life', '(QOL) survey, the Functional Assessment of Cancer Therapy-', 'General (FACT-G), will be administered at baseline, after 3 and', '6 cycles of treatment (cycle 4 and treatment discontinuation), and', 'at 3 months after treatment discontinuation.', 'DURATION:', '7 months', 'PRIMARY OBJECTIVE:', 'To evaluate the longitudinal quality of life of participants with', 'HIV-associated KS during treatment with vincristine and', 'bleomycin at a single institution in East Africa.', 'SECONDARY', 'To explore baseline and time-dependent correlates of', 'OBJECTIVE:', 'improvements in quality of life.', 'EXPLORATORY', 'To assess quality control (completeness and accuracy) in data', 'OBJECTIVE:', 'capture of adverse events, clinical benefit, and objective response', 'for site evaluation and training purposes.', 'AMC-S007 (Version 2.0) 20MAR2018', '7', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}